Biotech Values

[JohnWayne]

MRK - all fair points, though I'm much more bullish about PD1+chemo uptake. Remember that the OS curve in KN021G was still quite immature, and the ORR is higher for Keytruda + chemo in the <1% patients than it is for Keytruda alone in >50%.